Form D · Biotechnology
Grid Therapeutics LLC
Durham, NC · CIK 0001682338
Offering snapshot reported Jan 5, 2023 · SEC filing
- Reported sold
- $1.74M Offering amount: $1.74M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 19, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 5, 2023 | Initial | $1,740,000 | No comparison | 11 | SEC filing |
| Dec 9, 2020 | Initial | $1,909,367 | No comparison | 7 | SEC filing |
| Mar 29, 2018 | Initial | $4,540,451 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-469789
Source: Form D, filed Jan 5, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Scott Lyman | Executive |
| Paolo Paoletti | Director |
| Richard Parker | Director |
| Thomas Patz | Director, Executive |
| Edward F. Patz, Jr. | Director, Executive, Promoter |
| Kevin Schulman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
The Imperial Building, 215 Morris St Suite 300
Durham, NC, 27701
Durham, NC, 27701